Biotech Investment Outlook Remains Strong Despite Jitters
Executive Summary
Despite the recent volatility in the stock market, experts and industry insiders at the BIO CEO & Investor conference in New York said biotech remains a leading area to invest, predicting continued VC investment and more M&A ahead.
You may also be interested in...
Finance Watch: Another Mega-Round As Moderna Bucks Biopharma's IPO Trend
Moderna raised $500m to fund its growing pipeline, choosing once again to stay private rather than pursue an IPO. Also, AvroBio closed a $60m Series B round to advance its gene therapies for lysosomal storage disorders, Seattle Genetics led recent public company financings, and Vical is restructuring.
Radius Business Review Ends In Sale To Investment Funds
Gurnet Point Capital and Patient Square Capital will buy Radius Health for approximately $890m, including a contingent value right dependent on sales growth for osteoporosis drug Tymlos.
What Sanofi Early Research Chief Scientist Frank Nestle Is Most Excited About
Sanofi's Nestle talked to In Vivo about the company's early pipeline, the emerging technologies he thinks are most promising, and tapping external innovation.